Nuvalent Insider Trades Reveal Confidence as Antibody Pipeline Advances Toward FDA Fast‑Track Approval
Nuvalent’s March 30 insider trades show disciplined liquidity management while leaders remain optimistic about its antibody pipeline and upcoming FDA/EMA approvals.
4 minutes to read